Secondary outcome: clinical flare · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: CLASI · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Secondary outcome: Dermatology Quality of Life measure · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Adverse events: severe · patients with cutaneous disease in systemic lupus erythematosus
Oral chloroquine showed no clear difference in adverse events: severe compared with placebo (low certainty).
1 finding from 1 review
Minor adverse events · patients with cutaneous disease in systemic lupus erythematosus
1 finding from 1 review
Change in disability score · children and adults with SMA types II and III
2 findings from 1 review
Muscle strength · children and adults with SMA types II and III
1 finding from 1 review
Acquiring the ability to stand or walk · children and adults with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in quality of life · children and adults with SMA types II and III
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Change in pulmonary function · children and adults with SMA types II and III
1 finding from 1 review
Time from beginning of treatment until death or full‐time ventilation · children and adults with SMA types II and III
1 finding from 1 review
Adverse events related to treatment · children and adults with SMA types II and III
1 finding from 1 review
Persons with protective humoral response (Range of · infants
IPV‐OPV showed no clear difference in persons with protective humoral response (Range of compared with IPV (moderate certainty).
1 finding from 1 review
Persons with protective humoral response (Range of · preventing poliomyelitis
IPV(3)‐OPV showed no clear difference in persons with protective humoral response ( compared with IPV(2)‐OPV (moderate certainty).
1 finding from 1 review
Persons with protective humoral response (Range of · infants
IPV‐OPV showed no clear difference in persons with protective humoral response (Range of compared with OPV (moderate certainty).
1 finding from 1 review
Clearance, as assessed by a clinician at any · infantile haemangiomas (strawberry birthmarks) of the skin
Oral propranolol probably leads to higher clearance, as assessed by a clinician at any compared with placebo (moderate certainty).
1 finding from 1 review
Clearance, as assessed by a clinician at any · infantile haemangiomas (strawberry birthmarks) of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
A subjective measure of improvement, as assessed by the parent or child, at any · infantile haemangiomas (strawberry birthmarks) of the skin
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events experienced at short or long term ‐ general adverse events 24 weeks' · infantile haemangiomas (strawberry birthmarks) of the skin
It is very uncertain whether oral propranolol changes adverse events experienced at short or long term ‐ general adverse… compared with topical timolol (very low certainty).
1 finding from 1 review
Other measures of resolution, as assessed by a clinician, at any · infantile haemangiomas (strawberry birthmarks) of the skin
Oral propranolol showed no clear difference in other measures of resolution, as assessed by a clinician, at any compared with topical timolol (low certainty).
1 finding from 1 review